MHRA
- Status: likely_approved
🇬🇧 Hu3F8 in United Kingdom
Hu3F8 (NAXITAMAB) regulatory status in United Kingdom.
Marketing authorisation
Hu3F8 in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Oncology approved in United Kingdom
Frequently asked questions
Is Hu3F8 approved in United Kingdom?
Yes. MHRA has authorised it.
Who is the marketing authorisation holder for Hu3F8 in United Kingdom?
Y-Mabs Therapeutics Inc is the originator. The local marketing authorisation holder may differ — check the official source linked above.